Casi pharmaceuticals files annual report on form 20-f for fiscal year 2022

Beijing , april 26, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi) ("casi" or the "company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on form 20-f for the fiscal year ended december 31, 2022, with the u.s. securities and exchange commission ("sec") on april 26, 2023. the annual report can be accessed on the company's investor relations website at https://www.casipharmaceuticals.com/investor-relations/ as well as the sec's website at https://www.sec.gov/.
CASI Ratings Summary
CASI Quant Ranking